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Abstract
Background and Objectives—For patients with cutaneous melanoma, primary tumors located
in the head and neck is associated with poor outcomes. The reason for this difference and whether
it is applicable to all locations within the head and neck remains unclear. We hypothesized that
scalp melanoma is uniquely distinguished from other anatomic sites and is independently
responsible for the poor prognosis of head and neck melanoma.
Methods—Query and analysis of a prospectively maintained melanoma database of all patients
treated for primary cutaneous melanoma from 1971 – 2010.
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Results—Of 11,384 patients identified, 7% (n=799) of lesions originated on the scalp. Scalp
primaries were more often found in males and were associated with increased Breslow thickness
and were more frequently ulcerated compared to all other anatomic sites (p=0.0001). On
multivariate analysis, scalp location was an independent predictor of worse melanoma-specific
(HR 1.75; CI 1.50–2.04; p<0.0001) and overall survival (HR 1.62; CI 1.41–1.86: p<0.0001).
Conclusions—This, the largest series examining scalp melanoma, confirms that scalp location is
independently responsible for the negative prognosis associated with head and neck melanoma.
Although the pathophysiology of this difference remains to be determined, these data argue for
more rigorous surveillance of this anatomic location.
Keywords
Primary cutaneous melanoma; scalp; prognosis; outcomes
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Introduction
Despite heightened public awareness and improvement in early detection through screening
programs, cutaneous melanoma continues to represent one of several cancers with increasing
incidence over the last several decades.[1] In particular, melanoma arising from the head and
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neck region as a subgroup is being diagnosed with increased frequency.[2] Primary
cutaneous melanoma of the head and neck consists of lesions arising on the scalp, face, ears,
and neck, each occurring with distinct individual frequencies.[3] As a group, head and neck
melanoma has long been associated with a worse overall prognosis compared to cutaneous
melanoma arising from all other anatomic sites.[4] Whether these differences in long term
outcomes may be attributed to unique anatomic, biologic or environmental factors remains
unclear.
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Melanoma arising on the scalp, as a subset of head and neck melanoma, has in the past been
recognized as a “high-risk” anatomic location.[5–7] Large population based studies using
the Surveillance, Epidemiology and End Results (SEER) database have suggested that scalp
location may be an independent factor contributing to negative outcomes, in particular worse
melanoma-specific and overall survival.[8, 9] Unfortunately, these studies have been
constrained by the fact that scalp and neck melanoma are a combined category in the SEER
database, so delineating the true impact of scalp location alone was not possible. In smaller
series, examining the relative impact of individual sites of the head and neck generated
conflicting results.[10, 11]
Therefore, to our knowledge, the clinical implication of scalp location on head and neck
melanoma has not been adequately defined. We hypothesized that the scalp is associated
with an outcome profile that distinguishes it from all other anatomic sites and is responsible
for the generally poor prognosis attributed to melanoma of the head and neck.

Methods
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We queried our prospectively maintained database from 1971 through 2010 for all patients
diagnosed with cutaneous melanoma and having a known primary site. In order to avoid
referral bias favoring recurrent cases as well as the effect of treatment delay due to referral
time, analysis was limited to patients who were treated at our institution within 4 months of
their initial diagnosis. Patients with more than one primary melanoma were excluded from
analysis. Anatomic sites of the primary cutaneous melanoma were classified into the
following subgroups: scalp, face/neck/ear, trunk and extremity.
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Treatment consisted of wide local excision with excision margins determined by
recommendations current during the treatment era as well as sentinel lymph node biopsy
when indicated based on histopathological findings of the initial biopsy specimen. Clinical
follow up consisted of complete dermatologic and physical examination every 3 months
during the first 2 years and every 4–6 months for the next 3 years and then annually
thereafter. Routine blood work including complete blood count, comprehensive metabolic
panel and lactate dehydrogenase as well as radiographic studies were obtained annually
when indicated based on pathologic stage.
Clinical factors such as age and gender as well as histopathological features including
Breslow thickness, presence of ulceration, number of positive lymph nodes when examined,
and overall stage based on the American Joint Committee on Cancer Staging Manual[12]
were compared between anatomic sites of the primary cutaneous melanoma using chi-square
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test. Melanoma-specific (MSS) and overall survival (OS) by primary site were analyzed and
compared using Kaplan-Meier method and compared using the log-rank test. In order to
account for survival differences based on stage, stage for stage survival analysis was
performed. In order to identify significant independent predictors of 5-year melanomaspecific (MSS) and overall survival (OS), multivariable analysis using Cox proportionalhazards model was performed using a step-wise selection procedure to select the factors
included in the final model.

Results
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A total of 11,384 patients with a known primary melanoma were treated at our institution
between January 1, 1971 and December 31, 2010. Of those 7% (n=799) originated on the
scalp. The remainder of head and neck melanomas (face/neck/ear) consisted of 11%
(n=1,241) of all melanomas treated at our center during the study period (Table 1). Males
made up the majority (58%) of cases of melanoma and male gender was more common
among all anatomic sites except extremity melanoma, which was more common among
females. The proportion of males presenting with scalp lesions were significantly greater
than any other anatomic site (80%, p=0.0001). Patients with trunk melanoma were
significantly younger at the time of diagnosis compared to all other anatomic sites
(p<0.0001). On average, lesions of the scalp were thicker at presentation (2.6 mm) compared
to melanomas on the remainder of the head and neck (1.7 mm) (p<0.0001). In addition,
presence of ulceration was less frequently identified in non-scalp head and neck locations
compared to lesions of the scalp (10% vs. 16%, p=0.0001) (Table 2). Tumor-positive lymph
nodes were more commonly associated with scalp primaries (20%) than any other anatomic
site (p=0.0001).

Author Manuscript

On univariate analysis, scalp location was associated with significantly reduced 5-year OS
for all stages compared to all other anatomic sites (p<0.0001) (Figure 1a). When stage IV
patients were excluded from analysis a statistically significant worse overall survival
remained (p<0.0001) among scalp melanoma patients compared to the other groups (Figure
1b). This effect persisted when anatomic site was compared stage for stage among stage I
and II patients (Figure 1c) as well as stage III patients alone (Figure 1d).
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Multivariable analysis was performed to identify independent predictors of reduced 5-year
MSS and OS. The analysis included common prognostic variables such as age, sex, primary
anatomic site, tumor thickness categorized by T-stage, presence of ulceration, and lymph
node status. Analysis revealed that scalp location was independently associated with worse
MSS (HR 1.75; CI 1.50–2.04; p<0.0001) and OS (HR 1.62; CI 1.41–1.86; p<0.0001)
compared to all other anatomic sites (Table 3). Other head and neck primary tumor locations
were not significantly associated with outcomes worse than extremity, the reference site.
Age, sex, T stage, ulceration and nodal status were also significant.
Given the significantly worse MSS and OS associated with primary lesions of the scalp, we
elected to perform additional analysis to determine if this negative affect on survival could
be attributed to higher rates of developing metastatic disease. As demonstrated in Figure 2,
scalp location had worse distant disease-free survival compared to all other anatomic sites.
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Furthermore, on multivariable analysis, scalp location was independently associated with a
2-fold worse distant disease-free survival (HR 2.06; CI 1.79–2.38; p<0.0001).

Discussion
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The role of primary anatomic site as a prognostic indicator in cutaneous melanoma has been
debated for decades.[5–7] Although several studies have attempted to elucidate the impact of
anatomic site in the context of head and neck melanoma in the past, the relative impact of
scalp location alone has remained unclear. Urist et al. published an early series on head and
neck melanoma in 534 clinically stage I patients and noted that patients with scalp and neck
melanoma had a worse prognosis than tumors located on the face or ear[4]. A more recent
study by Leong et al. examined the impact of sentinel node status and other common
prognostic factors on outcomes in a cohort of 629 patients with head and neck melanoma
who underwent sentinel lymph node biopsy. This study reaffirmed that tumor site was
indeed an independent predictor of mortality with scalp location being associated with the
highest rate of recurrence and a more than 3-fold greater mortality than tumors of the face.
[13] In the Sunbelt Melanoma Trial, among patients who underwent sentinel lymph node
biopsy for melanomas > 1.0 mm in thickness and clinically negative nodal disease, scalp and
non-scalp head and neck melanoma had differing clinical and histopathological features that
affected long term outcomes. Of their 109 scalp melanoma patients, sentinel lymph node
status was the strongest predictor of overall survival while in non-scalp melanoma patients,
Breslow thickness and presence of ulceration were the primary predictors associated with
reduced survival.[14] Unfortunately, while each of these series is informative, conclusions
drawn are inherently limited by the small populations of patients examined. In order to
address, this limitation, large population-based database analyses have been performed and
have produced similar results. Using the SEER database, scalp and neck melanoma were
associated with significantly decreased MSS and OS compared with other areas of the head
and neck.[8, 9] The most recent of these studies by Tseng et al. featured a robust number of
patients (n=27,097) of which 34% presented with melanoma of the scalp or neck.
Unfortunately, SEER does not differentiate between scalp and neck melanoma, instead
combining both of these anatomic sites into one category for analysis. Therefore, it is
impossible to assess the true impact of scalp location alone.
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In the current study, we sought to compare a pure population of primary cutaneous scalp
melanoma patients to all other anatomic sites at a single institution using a large
prospectively maintained melanoma database. We found that non-scalp head and neck
melanoma had similar 5-year MSS and OS compared to melanoma of the trunk and
extremities. Conversely, scalp melanoma was associated with significantly worse 5-year
MSS and OS. Even after excluding stage IV patients, scalp primary site, thicker Breslow,
lymph node positivity, presence of ulceration, older age and male gender were all found to
be associated with significantly worse overall and melanoma-specific survival. Taken
together these findings suggest that scalp melanoma represents a distinct entity and is
probably responsible for the generally poor prognosis associated with head and neck
melanoma. In addition, scalp melanoma appears to behave in a more aggressive fashion
compared to melanoma originating from other anatomic sites.
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Several theories have been proposed to explain why scalp melanoma may be associated with
worse outcomes compared to melanoma originating from other anatomic sites. The
lymphatic drainage pattern of the scalp is complex and can often be variable and
unpredictable.[15–17] To highlight this fact, it has previously been reported that the rate of
false-negative sentinel lymph node biopsy in head and neck melanoma may be as high as
32%.[18] Therefore, anatomic variations in lymphatic drainage patterns of the head and neck
may predispose to greater risk of distant site recurrence. This was demonstrated in the
current study, as scalp location was independently associated with worse distant disease-free
survival compared to all other anatomic sites. In addition, it has been hypothesized that
given anatomic constraints of the scalp, patients may undergo inadequate excision
predisposing to higher rates of local recurrence.[19] Finally, as shown in this study,
melanoma of the scalp typically presents at more advanced stages with thicker lesions, more
frequently are ulcerated and more commonly are associated with nodal involvement. Taken
together, these findings may suggest that scalp lesions go unrecognized due to their location
or possibly are associated with longer delay times between time of patient recognition and
initial presentation to a health care provider.
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Recently, mutations in the N-ras oncogene have been recognized as a common genetic
mutation occurring in cutaneous melanoma with an incidence as high as 18%.[20] This
mutation has been associated with specific histologic subtypes of melanoma as well as
distinctive tumor locations, predominately being found in nodular melanoma arising in the
setting of areas of chronic sun-damaged skin secondary to exposure to ultraviolet radiation.
[20, 21] Head and neck melanoma, given their anatomic location and propensity for sun
exposure, appears to be particularly susceptible to N-ras mutations. Jiveskog et al. compared
frequencies of N-ras mutations between sun-exposed areas of the head and neck to
unexposed regions of the body and found N-ras to be mutated in 32% of head and neck
melanoma specimens, but only 7% of melanomas developing in unexposed sites.[22] N-ras
mutations have also been shown to be associated with thicker lesions and have higher rates
of mitotic activity. Furthermore, N-ras mutation appears to be an independent adverse
prognostic factor associated with decreased MSS (HR 2.96, p=0.04).[23] Therefore, a
complex combination of anatomic, biologic and environmental factors may be contributing
to the aggressive nature and pathogenesis of scalp melanoma.
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There are several limitations to the current study. Given the duration of the studied time
period, significant variations in standard staging procedures undoubtedly occurred, which
may make the study population somewhat heterogeneous. In addition, there may exist a
component of referral bias among the cohort of patients studied given we are a tertiary
melanoma-referral center. However, referral bias would be unlikely to selectively affect
scalp melanomas, and the extent of this bias should be limited by our exclusion of patients
not seen at our center within 4 months of their initial diagnosis or with multiple primary
melanomas. Finally, our multivariable analysis included T and N stage independently rather
than AJCC staging because of the issue of collinearity in multivariable analysis, since T and
N stage are factors determining AJCC stage. Nonetheless, analysis was repeated using AJCC
stage and similar results were obtained.
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In summary, scalp melanoma appears to present at later stage and behave more aggressively
than melanoma from all other anatomic sites. Anatomic, biologic and environmental factors
may contribute to the pathogenesis of scalp melanoma. Further studies to elucidate the
unique characteristics of scalp melanoma are warranted. Clinically, decisions concerning
indication for sentinel lymph node biopsy in thin melanomas of the scalp should be made in
light of these findings. In addition, closer follow-up may be warranted among these patients
due to increased rates of recurrence. Non-scalp head and neck melanoma may not carry as
negative a prognosis as previously thought. These findings support increased attention to the
scalp as a component of skin surveillance in an effort to improve early detection and
improve outcomes.

Conclusion
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We report the largest series of scalp melanoma to date. Scalp melanoma is associated with
reduced melanoma-specific and overall survival compared to non-scalp head and neck, trunk
and extremity melanoma. Thus, scalp melanoma alone may be responsible for the overall
poor long term outcomes of head and neck melanoma as a whole. Additional studies are
warranted to ascertain unique biologic, anatomic or environmental factors contributing to the
pathogenesis of scalp melanoma.
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Figure 1.

Comparison of 5-Year Overall Survival for Cutaneous Melanoma Stratified by Anatomic
Site for A) All Stages, B) with Stage IV Excluded, C) Stage I and II Only and D) Stage III
Only
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Figure 2.

Comparison of 5-year Distant Disease-Free Survival Stratified by Anatomic Site of Primary
Cutaneous Melanoma, All Stages
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Comparison of Demographics and Histopathological Characteristics for Patients with Scalp vs Non-Scalp
Head and Neck Melanoma
Face/Neck/Ear

Scalp

Total

n=1241

n=799

n=2040

Male

860 (69)

638 (80)

1498 (73)

Female

381 (31)

161 (20)

542 (27)

56 +/− 16.8

54 +/− 18.0

<0.0001

1.7 +/− 1.6

2.6 +/− 3.2

<0.0001

Absent

787 (63)

467 (58)

1254 (62)

Present

122 (10)

125 (16)

247 (12)

Unknown

332 (27)

207 (26)

539 (26)

N0

406 (33)

263 (33)

669 (33)

N1

57 (5)

75 (9)

132 (6)

N2

36 (3)

49 (6)

85 (4)

P-value
Variable
Gender
<0.0001

Age
Mean +/− SD
Breslow
Mean +/− SD
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Ulceration
0.0004

Nodal stage

N3

13 (1)

42 (5)

55 (3)

729 (59)

370 (46)

1099 (54)

I/II

798 (64)

416 (52)

1214 (60)

III

216 (17)

241 (30)

457 (22)

IV

209 (17)

132 (17)

341 (17)

18 (2)

10 (1)

28 (1)

Unknown

<0.0001

AJCC Stage
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Unknown

<0.0001

AJCC = American Joint Committee on Cancer
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Cox Proportional-Hazards Model of 5-Year Melanoma-Specific, Overall and Distant-Disease Free Survival
Multivariable 5-Year MSS

Multivariable 5-Year OS

Multivariable 5-Year DDFS

HR (95% CI), P-value

HR (95% CI), P-value

HR (95% CI), P-value

Male Sex

1.27 (1.16–1.38), <.0001

1.26 (1.16–1.37), <0.0001

1.25 (1.14–1.36), <.0001

Age (continuous)

1.01 (1.01–1.01), <.0001

1.02 (1.02–1.02), <0.0001

1.00 (1.00–1.01), 0.0001

Variable

Primary Site
Extremity (ref)
Scalp

**

**

**

1.75 (1.50–2.04), <.0001

1.62 (1.41–1.86), <.0001

2.06 (1.79–2.38), <.0001

Author Manuscript

Face/Neck/Ear

1.15 (0.98–1.34), 0.0930

1.13 (0.99–1.30), 0.0770

1.37 (1.19–1.59), <.0001

Trunk

1.36 (1.22–1.51), <.0001

1.27 (1.16–1.39), <.0001

1.37 (1.24–1.52), <.0001

**

**

**

T2: 1.01–2.00

2.18 (1.87–2.55), <.0001

1.89 (1.65–2.15), <.0001

2.30 (2.00–2.65), <.0001

T3: 2.01–4.00

3.93 (3.37–4.58), <.0001

3.11 (2.73–3.55), <.0001

3.68 (3.19–4.25), <.0001

T4: >4.00

5.24 (4.43–6.20), <.0001

4.13 (3.57–4.78), <.0001

5.03 (4.29–5.9), <.0001

T: Unknown

3.23 (2.78–3.75), <.0001

2.41 (2.12–2.74), <.0001

2.94 (2.56–3.38), <.0001

**

**

**

Present

1.95 (1.74–2.18), <.0001

1.79 (1.62–1.98), <.0001

1.92 (1.72–2.14), <.0001

Unknown

1.98 (1.80–2.19), <.0001

1.88 (1.72–2.05), <.0001

2.18 (1.98–2.39), <.0001

**

**

**

Positive

3.01 (2.68–3.37), <.0001

2.77 (2.50–3.07), <.0001

2.58 (2.31–2.88), <.0001

Unknown

1.32 (1.18–1.46), <.0001

1.31 (1.19–1.44), <.0001

1.28 (1.15–1.41), <.0001

T stage
T1: 0.01–1.00 (ref)

Ulceration
Absent (ref)

Lymph Node Status
Negative (ref)

Author Manuscript
Author Manuscript
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